
    
      This clinical trial is to assess the efficacy of Curcuminoids, EPA (Omega-3), Astaxanthin and
      GLA for improving inflammation and endothelial reactivity over a four week intervention
      period in individuals with metabolic syndrome. The study also examines the effect of
      Curcuminoids, EPA (Omega-3), Astaxanthin and GLA administration on other markers of
      cardiovascular function and cardiovascular disease risk including Total, LDL and
      HDL-Cholesterol, Triglycerides, and a multitude of inflammatory markers.
    
  